L’anticorps Lapin Polyclonal anti-MAGEA4 a été validé pour WB, ELISA, IHC (p) et IF. Il convient pour détecter MAGEA4 dans des échantillons de Humain, Rat et Souris.
N° du produit ABIN6992141
Aperçu rapide pour MAGEA4 anticorps (N-Term) (ABIN6992141)
MAGEA4 antibody is human specific. At least four isoforms of MAGEA4 are known to exist.
Purification
MAGEA4 antibody is affinity chromatography purified via peptide column.
Immunogène
MAGEA4 antibody was raised against a 16 amino acid peptide near the amino terminus of human MAGEA4. The immunogen is located within the first 50 amino acids of MAGEA4.
MAGEA4 antibody can be used for detection of MAGEA4 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
MAGEA4 antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
MAGEA4 antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Antigène
MAGEA4
(Melanoma Antigen Family A, 4 (MAGEA4))
Autre désignation
MAGEA4
Sujet
MAGEA4 is a member of the melanoma-associated antigen family that consists of a number of antigens recognized by cytotoxic T lymphocytes (1). MAGEA4 may serve as a target for antitumoral vaccination and may play a role in embryonal development and tumor transformation or aspects of tumor progression. It is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma and have been implicated in some hereditary disorders, such as dyskeratosis congenital (2-4).